Construction and Evaluation of Clinical Prediction Model for Immunotherapy-related Adverse Events and Clinical Benefit in Cancer Patients Receiving Immune Checkpoint Inhibitors Based on Serum Cytokine Levels.

There was also a nonsignificant trend toward longer OS if the onset of irAEs occurred >3 months after starting ICI therapy. 39 Furthermore, patients who developed at least 2 irAEs had improved outcomes compared with patients with a single irAE, and those with a single irAE exhibited better outcomes than those who developed no irAEs. 40 These studies performed subgroup analyses of the types of irAEs that exhibited better outcomes; generally, cutaneous and endocrinological irAEs performed better.

also in 5,406 other papers